Company: SUPN
Filing Date: 2025-06-16
Form Type: SC TO-C
Source: 0001104659-25-059956
Chunk: 3

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-06-16
Form: SC TO-C
Chunk 3
---
,
business partners and distribution channels to patients; the occurrence of any event, change or other circumstance that could give rise
to the termination of the acquisition agreement; the risk that stockholder litigation in connection with the proposed transaction may
result in significant costs of defense, indemnification and liability; the failure of the closing conditions set forth in the acquisition
agreement to be satisfied or waived; Supernus’ ability to sustain and increase its profitability; Supernus’ ability to raise
sufficient capital to fully implement its corporate strategy; the implementation of Supernus’ corporate strategy; Supernus’
future financial performance and projected expenditures; Supernus’ ability to increase the number of prescriptions written for each
of its products and products acquired through the acquisition of Sage; Supernus’ ability to increase its net revenue from its products
and products acquired through the acquisition of Sage; Supernus’ ability to commercialize its products including Qelbree; Supernus’
ability to enter into future collaborations with pharmaceutical companies and academic institutions or to obtain funding from government
agencies; Supernus’ product research and development activities, including the timing and progress of Supernus’ clinical trials,
and projected expenditures; Supernus’ ability to receive, and the timing of any receipt of, regulatory approvals to develop and
commercialize Supernus’ product candidates; Supernus’ ability to protect its intellectual property and operate its business
without infringing upon the intellectual property rights of others; Supernus’ expectations regarding federal, state and foreign
regulatory requirements; the therapeutic benefits, effectiveness and safety of Supernus’ product candidates; the accuracy of Supernus’
estimates of the size and characteristics of the markets that may be addressed by its product candidates; Supernus’ ability to increase
its manufacturing capabilities for its products and product candidates; Supernus’ projected markets and growth in markets; Supernus’
product formulations and patient needs and potential funding sources; Supernus’ staffing needs; and other risk factors set forth
from time to time in Supernus’ filings with the Securities and Exchange Commission made pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934, as amended. Supernus undertakes no obligation to update the information in this communication to reflect events
or circumstances after the date hereof or to reflect the occurrence of anticipated or unanticipated events.

AboutSupernus

Supernus Pharmaceuticals is a biopharmaceutical
company focused on developing and commercializing products for the treatment of central nervous system (C